Scott Lippman MD will lead Scott Lippman MD will be the director of the PreCancer Genome Atlas. This NCI-sponsored project examines in space and time every molecular, cell and structural characteristics of the premalignant lesions and how they evolve into cancers that are invasive. He will continue to serve as associate vice chancellor for cancer research and care at University of California San Diego and transition from his current role as director of the Moores Cancer Center at UC San Diego Health.
Scott Lippman, MD, will continue to serve as associate vice chancellor for cancer research and treatment at University of California San Diego and will be stepping down from his current position as director of Moores Cancer Center at UC San Diego Health.
Lippman, who became director of Moores Cancer Center in 2012, oversaw a period of notable growth, collaboration and research. He will remain as director during a national search for his successor.
Dr. Lippman has not just achieved all we could have imagined during his time as director, but he has also exceeded our expectations. Oncology at UC San Diego Health is now one of the leading cancer centers at an academic level in the world, much of it due to Dr. Lippman’s leadership. Dr. Lippman is also directing the cancer program across the entire UC system.”
David Brenner, MD, vice chancellor for health sciences, UC San Diego
Lippman who is also a Distinguished Prof of Medicine and holds the Chugai Pharmaceutical Chair for Cancer and Cancer, said it has been an extraordinary 10 years. “It is exciting to assume the new position of leader at UC San Diego Health, and continue to provide patient care and research to make a positive difference in the lives of patients. I am excited to welcome a new Director to oversee the next generation of Moores Cancer Center. It is going to be an amazing experience and I’m eager to see what the future holds for this center..
Lippman’s tenure has been highlighted by significant clinical growth to 400 nurses, doctors and staff who serve more than 100,000 patients per year, and facilities expansion to five clinical sites in the region and three affiliations.
Under his direction under his leadership, the Pauline and Stanley Foster Pavilion for Cancer Care was opened in 2016; the Koman Family Outpatient Pavilion in 2018; and the Center for Novel Therapeutics in 2019. The University of California Regents approved the $2.5 billion Hillcrest Medical Campus Redevelopment in October of 2018. It will include a new outpatient cancer pavilion. The pavilion is expected to be completed by the end of 2025.
“Dr. Lippman has made us extremely proud of our cancer care,” said Patty Maysent the CEO of UC San Diego Health. “Our mission is based on the notion that no one should ever have to leave San Diego to receive world-class health treatment. Dr. Lippman and his team at Moores Cancer Center have made the dream a reality. I am grateful to him for his unsurpassed determination and unwavering dedication to making a major difference for the patient.”
This year, U.S. News & World Report ranked Moores Cancer Center #17 in the nation which is up from 47 in 2020.
“I am extremely proud of the exceptional accomplishments and impact of our faculty and staff as well as the increasing national recognition we have received in places such as the U.S. News & World Report rankings and our ongoing, productive collaborations with the other notable NCI Comprehensive Cancer Centers,” said Lippman who founded both the University of California Cancer Consortium and the San Diego NCI Cancer Centers Council (C3).
Lippman also led Moores Cancer Center through two highest-scoring competitive NCI renewals, earning an Exceptional designation, a distinction that is only awarded to the top 1 percent of cancer centers. He also redeveloped the philanthropic program, boosting annual charitable donations from $8million to $60 million by the fiscal year 2021.
“Developing the highest-quality cancer care in San Diego has always been my priority from the beginning,” stated Chancellor Pradeep K.Khosla.
“We are forever grateful to Dr. Lippman for his impact on research and treatment for cancer and we are thrilled that he will assume a broader role at UC San Diego as associate vice chancellor for cancer research and treatment and will be focusing on high-priority strategic initiatives. His commitment to ensuring that our next director is successful is an affirmation of his strength of character as well as his commitment to the community.
Content Source: https://www.news-medical.net/news/20211129/UC-San-Diegos-Scott-Lippman-to-launch-and-lead-NCI-sponsored-PreCancer-Genome-Atlas.aspx
